CN103889454B - 重组成对碱性氨基酸蛋白酶的制剂 - Google Patents

重组成对碱性氨基酸蛋白酶的制剂 Download PDF

Info

Publication number
CN103889454B
CN103889454B CN201280038218.5A CN201280038218A CN103889454B CN 103889454 B CN103889454 B CN 103889454B CN 201280038218 A CN201280038218 A CN 201280038218A CN 103889454 B CN103889454 B CN 103889454B
Authority
CN
China
Prior art keywords
compositionss
furin
sugar
restructuring
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280038218.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103889454A (zh
Inventor
M·哈斯拉赫尔
A·齐特科维兹
C·怀特
K·弗兰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Hundred Deep Co
Hundred Deep LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hundred Deep Co, Hundred Deep LLC filed Critical Hundred Deep Co
Publication of CN103889454A publication Critical patent/CN103889454A/zh
Application granted granted Critical
Publication of CN103889454B publication Critical patent/CN103889454B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6454Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21075Furin (3.4.21.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280038218.5A 2011-06-02 2012-06-04 重组成对碱性氨基酸蛋白酶的制剂 Active CN103889454B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492712P 2011-06-02 2011-06-02
US61/492,712 2011-06-02
PCT/US2012/040790 WO2012167271A1 (en) 2011-06-02 2012-06-04 Formulations of recombinant furin

Publications (2)

Publication Number Publication Date
CN103889454A CN103889454A (zh) 2014-06-25
CN103889454B true CN103889454B (zh) 2017-04-05

Family

ID=46705014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280038218.5A Active CN103889454B (zh) 2011-06-02 2012-06-04 重组成对碱性氨基酸蛋白酶的制剂

Country Status (14)

Country Link
US (2) US8877473B2 (ko)
EP (1) EP2714087B1 (ko)
JP (2) JP5797837B2 (ko)
KR (1) KR102050609B1 (ko)
CN (1) CN103889454B (ko)
AR (1) AR086672A1 (ko)
AU (2) AU2012261813B2 (ko)
BR (1) BR112013030880B1 (ko)
CA (1) CA2837948C (ko)
ES (1) ES2715289T3 (ko)
RU (1) RU2610436C2 (ko)
SG (2) SG195261A1 (ko)
TW (1) TWI586802B (ko)
WO (1) WO2012167271A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416908B2 (ja) * 2013-08-20 2018-10-31 アドヴァンスド ポリマー モニタリング テクノロジーズ インコーポレイテッドAdvanced Polymer Monitoring Technologies, Inc. 同時複数試料光散乱検出装置及びその方法
TWI743023B (zh) * 2014-05-21 2021-10-21 日商Km生物醫藥股份有限公司 基質金屬蛋白酶 7(mmp-7)聚集體之單體化方法
TWI666319B (zh) * 2014-08-12 2019-07-21 美商巴克斯歐塔公司 在分泌furin之哺乳動物表現系統中生產經完全加工且具功能性之因子X
CN111183151B (zh) 2017-06-23 2024-06-07 武田药品工业株式会社 因子viii亚种的纯化

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
TR201809670T4 (tr) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları.
DE102006008613A1 (de) * 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
PT2157177E (pt) * 2007-05-22 2013-04-18 Baxter Int Processo de purificação preparativo para a furina humana
BRPI0821467B8 (pt) * 2007-12-31 2021-05-25 Baxalta GmbH composição de furina recombinante, método para produzir a composição de furina recombinante, e, método para produzir uma proteína madura utilizando a composição de furina recombinante

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"弗林蛋白酶:一种广泛参与前体蛋白切割的内切蛋白酶";王涛等;《医学分子生物学杂志》;20061231;第3卷(第3期);第202-205页 *

Also Published As

Publication number Publication date
TWI586802B (zh) 2017-06-11
EP2714087A1 (en) 2014-04-09
ES2715289T3 (es) 2019-06-03
US20120329128A1 (en) 2012-12-27
RU2610436C2 (ru) 2017-02-10
CN103889454A (zh) 2014-06-25
JP5797837B2 (ja) 2015-10-21
AU2012261813B2 (en) 2017-04-20
AR086672A1 (es) 2014-01-15
BR112013030880B1 (pt) 2022-04-12
CA2837948A1 (en) 2012-12-06
AU2012261813A1 (en) 2013-12-19
KR102050609B1 (ko) 2019-11-29
AU2017202050A1 (en) 2017-04-20
KR20140050625A (ko) 2014-04-29
BR112013030880A2 (pt) 2017-06-20
US9662376B2 (en) 2017-05-30
JP2014519506A (ja) 2014-08-14
WO2012167271A1 (en) 2012-12-06
TW201249989A (en) 2012-12-16
US8877473B2 (en) 2014-11-04
RU2013157927A (ru) 2015-07-20
JP6064007B2 (ja) 2017-01-18
US20150079068A1 (en) 2015-03-19
JP2016006106A (ja) 2016-01-14
SG10201604488TA (en) 2016-07-28
CA2837948C (en) 2018-08-21
EP2714087B1 (en) 2018-10-31
SG195261A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
CN103889454B (zh) 重组成对碱性氨基酸蛋白酶的制剂
JP2022037215A (ja) 凍結乾燥した組換え型vwf製剤
CN104224705B (zh) 稳定化的液体和冻干的adamts13制剂
US20190167797A1 (en) Stabilized factor ix formulations containing trehalose
JP2017075171A (ja) (ポリ)ペプチドのアンフォールディングを防止し、および/または(ポリ)ペプチドの(リ)フォールディングを誘導するための方法
ES2562256T3 (es) Purificación de FVW para aumentar la eliminación de virus sin envoltura lipídica
KR101989185B1 (ko) 원생동물 중 참게 인자 c 단백질의 재조합 생산을 위한 방법
JP2024001136A (ja) クロマトグラフィー法によるvwfとvwfプロペプチドの分離
KR101660533B1 (ko) 인간 푸린의 분취 정제 방법
Bai et al. Ghrelin promotion of oocyte maturation via ERK1/2 pathway in ovis aries
MASON ROSS TA MACGILLIVRAY

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160811

Address after: Aupu, Switzerland

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Illinois State

Applicant before: Baxter International Inc.

Applicant before: Bakst Helth Co., Ltd.

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Zug City

Co-patentee after: Hundred deep company

Patentee after: Hundred deep limited liability company

Address before: Aupu, Switzerland

Co-patentee before: Hundred deep company

Patentee before: Hundred deep limited liability company

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210702

Address after: Osaka

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Zug City

Patentee before: BAXALTA GmbH

Patentee before: Baishen Co.